Original Article
  

Association between HLA-DRB1.2 Genotypic Diversity and Cervical Cancer in Women Infected with the Human Papillomavirus

Abstract

Cervical cancer is a significant public health concern, particularly in women infected with the human papillomavirus (HPV). Recent evidence suggests that host genetic factors, specifically those related to the human leukocyte antigen (HLA) system, may also play a crucial role in determining susceptibility to cervical cancer in HPV-infected individuals.
In this study, 86 patients with HPV and 27 healthy donors were selected from May 2023 to February 2024. HLA-DRB1 genotypes were determined using polymerase chain reaction followed by high-resolution melting curve analysis (HRM). Genotype frequencies in patients were compared with those in the control group from donors.
Based on the HRM analysis, 10 genotypes were found in both patients and controls (profiles A-J). In the analysis of HLA-DRB1 genotypes, C, F, and I showed significant associations with HPV infection, indicating a possible protective effect against infection. Notably, genotype B was strongly linked to high-risk HPV, while genotype A was associated with low-risk HPV and is relevant to infection history. However, the remaining genotypes examined in the study did not exhibit significant associations with the analyzed parameters.
This study contributes valuable evidence regarding the role of HLA-DRB1 genotypes in cervical cancer susceptibility and highlights the potential clinical implications for risk assessment and targeted immunotherapies. The use of HRM for HLA typing offers advantages that are efficient, accurate, and scalable, making it suitable for large-scale studies and clinical applications.

1. Pimple S, Mishra G. Cancer cervix: Epidemiology and disease burden. CytoJournal. 2022;19:21.
2. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003;9(5):348-59.
3. Paaso A, Jaakola A, Syrjänen S, Louvanto K. From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host Immunity. Acta Cytol. 2019;63(2):148-58.
4. Mahdi BM. Introductory chapter: concept of human leukocyte antigen (HLA). human leukocyte antigen (HLA). 2019 Jan 18:1-8.5.
5. Suzuki K, Luo Y. Histone Acetylation and the Regulation of Major Histocompatibility Class II Gene Expression. Adv Protein Chem Struct Biol. 2017;106:71-111.
6. Kamiza AB, Kamiza S, Mathew CG. HLA-DRB1 alleles and cervical cancer: A meta-analysis of 36 case-control studies. Cancer Epidemiol. 2020;67:101748.
7. Latsoudis H, Stylianakis E, Mavroudi I, Kanterakis A, Pavlidis P, Georgopoulou A, Batsali A, et al. Significance of regional population HLA immunogenetic datasets in the efficacy of umbilical cord blood banks and marrow donor registries: a study of Cretan HLA genetic diversity. Cytotherapy. 2022;24(2):183-92.
8. Chambuso R, Ramesar R, Kaambo E, Denny L, Passmore JA, Williamson AL, et al. Human Leukocyte Antigen (HLA) Class II -DRB1 and -DQB1 Alleles and the Association with Cervical Cancer in HIV/HPV Co-Infected Women in South Africa. J Cancer. 2019;10(10):2145-52.
9. Kim N, Kwon JS, Kang WH, Yeom SI. High-Resolution Melting (HRM) Genotyping. Methods Mol Biol. 2023;2638:337-49.
10. Smith RA, Lam AK. Single Nucleotide Polymorphisms in Papillary Thyroid Carcinoma: Clinical Significance and Detection by High-Resolution Melting. Methods Mol Biol. 2022;2534: 149-59.
11. Wittwer CT, Hemmert AC, Kent JO, Rejali NA. DNA melting analysis. Mol Aspects Med. 2024;97.
12. Tucker EJ, Huynh BL. Genotyping by high-resolution melting analysis. Methods Mol Biol 2014;1145:59-66.
13. Zhang L, Ma X, You G, Zhang X, Fu Q. A novel multiplex HRM assay to detect clopidogrel resistance. Sci Rep. 2017;22 (1):16021.
14. Nathalang O, Intharanut K, Chidtrakoon S. High-resolution melting curve analysis to predict extended blood group phenotypes among Thai donors and patients. Transfus Med Hemother. 2022;22 (3):163-71.
15. Smith JM, S. N. a. J. T., HLA-DRB1*13 and its associated alleles are linked with persistent human papillomavirus (HPV) 16 infection. J Med Microbiol. 2015;64:530-6.
16. Wang SS TM, Schiffman M. Human leukocyte antigen (HLA) class I DRB1*04 alleles protect against persistent cervical neoplasia in women coinfected with oncogenic human papillomavirus (HPV) types. J Infect Dis. 2017;216(4):474-8.
17. Zhang QX, Zhong A. Association between human leukocyte antigen variants and human papillomavirus 16-positive cervical cancer. Biomed Res Int. 2018;16;570-81.
18. Bouza E, Martín Jiménez M, Alemany L, Arribas J, Bañares R, Barragán MB, et al. Overview of virus and cancer relationships. Position paper. Rev Esp Quimioter. 2021;34(6):525-55.
19. Chan PK, Cheung JL, Cheung TH, Lin CK, Siu SS, Yu MM, et al. HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese population. Gynecol Oncol. 2007;105(3):736-41.
20. Delahaye-Sourdeix M, Urayama KY, Gaborieau V, Veenstra R, Foll M, Chabrier A, Benavente Y, et al. A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev. 2015;24(12):1838-43.
Files
IssueArticles in Press QRcode
SectionOriginal Article(s)
Keywords
Cervical cancer HLA-DRB1.2 HRM MHC Papillomavirus
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Sedaghat S, Nikbakht Brujeni G, Shamsian SAA, Sohrabi Haghdoost N. Association between HLA-DRB1.2 Genotypic Diversity and Cervical Cancer in Women Infected with the Human Papillomavirus. Iran J Allergy Asthma Immunol. 2025;:1-10.